$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

$nwbo Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000114420417060217 Filed on November 20, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q4
Revenue	$148.0K	$88.00K	$70.00K
YoY Change	-6.92%	-43.95%	-91.89%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.560M	$5.290M	$4.490M
YoY Change	-0.44%	-18.24%	-39.65%
% of Gross Profit
Research & Development	$9.721M	$5.466M	$16.83M
YoY Change	-53.92%	-37.27%	-62.44%
% of Gross Profit
Depreciation & Amortization	$41.00K	$44.00K	$50.00K
YoY Change	-25.45%	-34.33%	150.0%
% of Gross Profit
Operating Expenses	$9.721M	$5.466M	$21.32M
YoY Change	-53.92%	-37.27%	-59.2%
Operating Profit	-$14.13M	-$10.67M
YoY Change	-44.61%	-29.01%
Interest Expense	$1.193M	$1.308M	-$3.060M
YoY Change	72.65%	79.42%	-111.2%
% of Operating Profit
Other Income/Expense, Net	-$2.300M		$0.00
YoY Change	57.53%		-100.0%
Pretax Income	-$23.27M	-$10.25M	-$30.71M
YoY Change	-20.39%	-27.72%	27.53%
Income Tax
% Of Pretax Income
Net Earnings	-$23.27M	-$10.25M	-$30.71M
YoY Change	-20.38%	-27.67%	27.54%
Net Earnings / Revenue	-15723.65%	-11651.14%	-43871.43%
Basic Earnings Per Share	-$0.08
Diluted Earnings Per Share	-$0.08	-$49.17K	-$240.3K
COMMON SHARES
Basic Shares Outstanding	281.5M shares	191.8M shares
Diluted Shares Outstanding	281.5M shares

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.050M	$20.00K	$6.190M
YoY Change	31.25%	-99.07%	-71.62%
Cash & Equivalents	$1.051M	$22.00K	$6.871M
Short-Term Investments
Other Short-Term Assets	$1.080M	$800.0K	$1.700M
YoY Change	-27.03%	-65.96%	-25.76%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$2.130M	$820.0K	$7.884M
YoY Change	-6.17%	-81.78%	-67.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$47.51M	$46.45M	$315.0K
YoY Change	2.06%	-0.94%	-33.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$110.0K	$120.0K	$148.0K
YoY Change	-8.33%	-45.45%	-22.11%
Total Long-Term Assets	$47.62M	$46.56M	$45.02M
YoY Change	2.04%	-1.16%	-3.58%
TOTAL ASSETS
Total Short-Term Assets	$2.130M	$820.0K	$7.884M
Total Long-Term Assets	$47.62M	$46.56M	$45.02M
Total Assets	$49.75M	$47.38M	$52.91M
YoY Change	1.66%	-8.2%	-25.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$44.95M	$37.52M	$12.38M
YoY Change	78.51%	88.64%	5.61%
Accrued Expenses			$901.0K
YoY Change			-31.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$2.760M
YoY Change		-100.0%	196.77%
Long-Term Debt Due	$11.54M	$17.44M	$20.75M
YoY Change	-45.28%	65.78%	83.14%
Total Short-Term Liabilities	$81.13M	$72.79M	$76.41M
YoY Change	50.35%	21.52%	17.93%
LONG-TERM LIABILITIES
Long-Term Debt	$11.45M	$9.840M	$3.000M
YoY Change		-7.87%	-71.54%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$11.45M	$9.840M	$3.000M
YoY Change		-7.87%	-71.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$81.13M	$72.79M	$76.41M
Total Long-Term Liabilities	$11.45M	$9.840M	$3.000M
Total Liabilities	$92.58M	$82.63M	$79.41M
YoY Change	71.57%	17.07%	5.21%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock			$687.1M
YoY Change			8.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$42.83M	-$35.24M	-$26.50M
YoY Change
Total Liabilities & Shareholders Equity	$49.75M	$47.38M	$52.91M
YoY Change	1.66%	-8.2%	-25.27%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q4
OPERATING ACTIVITIES
Net Income	-$23.27M	-$10.25M	-$30.71M
YoY Change	-20.38%	-27.67%	27.54%
Depreciation, Depletion And Amortization	$41.00K	$44.00K	$50.00K
YoY Change	-25.45%	-34.33%	150.0%
Cash From Operating Activities	-$5.720M	-$3.700M	-$14.09M
YoY Change	-41.39%	-73.94%	-39.35%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$10.00K	-$170.0K
YoY Change	-100.0%	-99.38%	-93.8%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	-$10.00K	-$170.0K
YoY Change	-100.0%	-99.38%	-93.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$360.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.100M	3.850M	17.49M
YoY Change	5.47%	-1.28%	-57.72%
NET CHANGE
Cash From Operating Activities	-5.720M	-3.700M	-14.09M
Cash From Investing Activities	0.000	-10.00K	-170.0K
Cash From Financing Activities	8.100M	3.850M	17.49M
Net Change In Cash	2.380M	140.0K	3.230M
YoY Change	-193.33%	-101.17%	-79.03%
FREE CASH FLOW
Cash From Operating Activities	-$5.720M	-$3.700M	-$14.09M
Capital Expenditures	$0.00	-$10.00K	-$170.0K
Free Cash Flow	-$5.720M	-$3.690M	-$13.92M
YoY Change	-38.43%	-70.67%	-32.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	4640000	USD
CY2016Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	9791000	USD
CY2017Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	17032000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	13239000	USD
CY2017Q3	nwbo	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	27916000	USD
CY2016Q4	nwbo	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	23393000	USD
CY2017Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	11883000	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4862000	USD
CY2017Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11447000	USD
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3000000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	92581000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	79405000	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	157000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	686972000	USD
CY2016Q4	nwbo	Development Stage Enterprise Deficit Accumulated During Development Stage1 DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage1	715476000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1848000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-26499000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52906000	USD
CY2017Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	3000000	USD
CY2017Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	5072000	USD
CY2016Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	6375000	USD
CY2016Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0	USD
CY2016Q3	us-gaap	Revenue From Grants RevenueFromGrants	159000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	159000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21094000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2668000	USD
CY2016Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	25675000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-29227000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	217587000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105501000	shares
CY2017Q3	nwbo	Deemed Dividend Related To Warrant Modification DeemedDividendRelatedToWarrantModification	0	USD
CY2016Q3	nwbo	Deemed Dividend Related To Warrant Modification DeemedDividendRelatedToWarrantModification	3007000	USD
	nwbo	Deemed Dividend Related To Warrant Modification DeemedDividendRelatedToWarrantModification	0	USD
	nwbo	Deemed Dividend Related To Warrant Modification DeemedDividendRelatedToWarrantModification	5647000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23271000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32234000	USD
CY2016Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-433000	USD
CY2017Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1975000	USD
CY2017Q3	us-gaap	Legal Fees LegalFees	1595000	USD
CY2016Q3	us-gaap	Legal Fees LegalFees	1913000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	281486000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	114836000	shares
	us-gaap	Revenue From Grants RevenueFromGrants	552000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43247000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7929000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	58570000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-58018000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-49508000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	304000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	304000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9254000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	37006000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-36702000	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2963000	USD
	us-gaap	Interest Expense InterestExpense	3695000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-46144000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	4104000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-433000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-10517000	USD
	us-gaap	Legal Fees LegalFees	7530000	USD
	us-gaap	Legal Fees LegalFees	7394000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-46144000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-55155000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-626000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y3M18D
CY2017Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	561000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28601000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23832000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1126000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	2201000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48382000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48345000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	856000	USD
	nwbo	Value Of Warrants Exercised For Cash ValueOfWarrantsExercisedForCash	2805000	USD
	nwbo	Adjustments To Additional Paid In Capital Reclassification AdjustmentsToAdditionalPaidInCapitalReclassification	2117000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2201000	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2540000	USD
	nwbo	Stock And Warrants Issued During Period Value Private Placement Net Of Offering Costs StockAndWarrantsIssuedDuringPeriodValuePrivatePlacementNetOfOfferingCosts	614000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1187000	USD
	nwbo	Stock And Warrants Issued During Period Value Conversion Of Debt And Accrued Interest StockAndWarrantsIssuedDuringPeriodValueConversionOfDebtAndAccruedInterest	14017000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	729000	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	3750000	USD
	nwbo	Stock Issued During Period Value Extinguishment Of Senior Convertible Notes StockIssuedDuringPeriodValueExtinguishmentOfSeniorConvertibleNotes	2054000	USD
	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	72000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41555000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21701000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4770000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	206000	USD
	nwbo	Increase Decrease In Prepaid Expense And Other Current Assets IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets	-617000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	135000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	141000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19995000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20820000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-4320000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	3944000	USD
	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	9509000	USD
	nwbo	Proceeds From Issuance Of Capital Stock And Warrants ProceedsFromIssuanceOfCapitalStockAndWarrants	13700000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	856000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1077000	USD
	nwbo	Loss On Extinguishment Of Debt LossOnExtinguishmentOfDebt	10067000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1158000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	639000	USD
	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	11836000	USD
	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-822000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	4864000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	2805000	USD
	us-gaap	Increase Decrease In Notes Payable Related Parties IncreaseDecreaseInNotesPayableRelatedParties	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1644000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5820000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21561000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6871000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23048000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1051000	USD
CY2016Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1487000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2805000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	8066000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	3258000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
	nwbo	Stock And Warrants Issued To Related Party Expenses StockAndWarrantsIssuedToRelatedPartyExpenses	0	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1551	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	11343	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	238	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12656	shares
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	405000	USD
	us-gaap	Depreciation Depreciation	141000	USD
	us-gaap	Depreciation Depreciation	135000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.25
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P5Y
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.5	pure
	nwbo	Stock And Warrants Issued To Related Party Expenses StockAndWarrantsIssuedToRelatedPartyExpenses	13654000	USD
	nwbo	Debt Instrument Premium DebtInstrumentPremium	407000	USD
	nwbo	Debt Instrument Premium DebtInstrumentPremium	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	729000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1616000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	926000	USD
	nwbo	Payment Of Warrants Excercise Offering Cost PaymentOfWarrantsExcerciseOfferingCost	0	USD
	nwbo	Payment Of Warrants Excercise Offering Cost PaymentOfWarrantsExcerciseOfferingCost	795000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1604000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	4368000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1697000	USD
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	8273000	USD
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	6391000	USD
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	14000	USD
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	4770000	USD
CY2017Q3	nwbo	Current Assets Less Payables CurrentAssetsLessPayables	79000000	USD
CY2017Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	27800000	USD
	nwbo	Trade Liabilities Waived By Related Partiesamount TradeLiabilitiesWaivedByRelatedPartiesamount	3750000	USD
	nwbo	Proceeds From Issuance Of Common Stock And Debt ProceedsFromIssuanceOfCommonStockAndDebt	24900000	USD
	us-gaap	Debt Instrument Increase Decrease For Period Net DebtInstrumentIncreaseDecreaseForPeriodNet	5000000	USD
CY2017Q3	us-gaap	Accrued Environmental Loss Contingencies Noncurrent AccruedEnvironmentalLossContingenciesNoncurrent	6200000	USD
	us-gaap	Site Contingency Loss Exposure In Excess Of Accrual Best Estimate SiteContingencyLossExposureInExcessOfAccrualBestEstimate	6200000	USD
CY2017Q3	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	4013000	USD
CY2017Q3	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	17690000	USD
CY2017Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	1794000	USD
CY2016Q4	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	5200000	USD
CY2016Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	10062000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	10062000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales	2117000	USD
	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-2963000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	4262000	USD
	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements Related To Conversion Of Sharesettled Debt FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlementsRelatedToConversionOfSharesettledDebt	1187000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	546000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	7255	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.56
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.25
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	9.9
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.32
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.49
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y10M24D
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	58278000	shares
	nwbo	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	0.47
CY2016	nwbo	Class Of Warrant Or Right Oustanding Remaining Contractual Term ClassOfWarrantOrRightOustandingRemainingContractualTerm	P3Y10M10D
	nwbo	Number Of Warrants Warrants Exercised For Cash NumberOfWarrantsWarrantsExercisedForCash	24327000	shares
CY2016Q4	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	1.78
	nwbo	Weighted Average Exercise Price Exercised For Cash WeightedAverageExercisePriceExercisedForCash	0.11
CY2017Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.14
CY2017Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	600000	USD
CY2017Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	300000	USD
	nwbo	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P4Y8M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y2M12D
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.25
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y9M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.96	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.02	pure
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	400000	USD
CY2017Q3	us-gaap	Notes Payable NotesPayable	135000	USD
CY2017Q3	us-gaap	Interest Expense Other InterestExpenseOther	5000	USD
CY2016Q3	us-gaap	Interest Expense Other InterestExpenseOther	2000	USD
CY2017Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	1193000	USD
CY2016Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	691000	USD
	us-gaap	Interest Expense Other InterestExpenseOther	10000	USD
	us-gaap	Interest Expense Other InterestExpenseOther	2000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	3695000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	2138000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	43601000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	230322000	shares
CY2017Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7500000	USD
CY2017Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	18800000	shares
CY2017Q1	nwbo	Shares Issued During Period Shares Upon Exercise Of Warrants SharesIssuedDuringPeriodSharesUponExerciseOfWarrants	3100000	shares
CY2017Q1	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	713000	USD
CY2017Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1400000	shares
CY2017Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.26
CY2017Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	360000	USD
CY2017Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2000000	USD
CY2017Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	11000000	shares
CY2017Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.18
CY2017Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1800000	USD
CY2017Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	900000	USD
CY2017Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	3900000	USD
CY2017Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1600000	USD
CY2017Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	500000	USD
CY2017Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	3300000	shares
	nwbo	Class Of Warrant Or Right Oustanding Remaining Contractual Term ClassOfWarrantOrRightOustandingRemainingContractualTerm	P3Y6M7D
	nwbo	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	191965000	shares
	nwbo	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	30878000	shares
CY2017Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	178967000	shares
	nwbo	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	1.18
CY2017Q3	nwbo	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	0.84
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	309675000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	157028000	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	309675000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	157028000	shares
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1457000	USD
CY2017Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	2297000	USD
CY2016Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1457000	USD
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	2297000	USD
	nwbo	Stock Issued During Period Value Issued For Non Cash Consideration StockIssuedDuringPeriodValueIssuedForNonCashConsideration	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 57.2pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></i></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In preparing condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, valuing environmental liabilities, estimating the fair value of financial instruments recorded as derivative liabilities, and estimating the useful lives of depreciable assets and whether impairment charges may apply.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	734000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	720000	USD
CY2017Q3	nwbo	Property Plant And Equipment Net Including Construction In Progress PropertyPlantAndEquipmentNetIncludingConstructionInProgress	47510000	USD
CY2016Q4	nwbo	Property Plant And Equipment Net Including Construction In Progress PropertyPlantAndEquipmentNetIncludingConstructionInProgress	44874000	USD
CY2017Q3	us-gaap	Depreciation Depreciation	41000	USD
CY2016Q3	us-gaap	Depreciation Depreciation	55000	USD
	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	-38000	USD
	nwbo	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	-70000	USD
	nwbo	Loss On Extinguishment Of Debt LossOnExtinguishmentOfDebt	433000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1187000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	nwbo	Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterest	10975000	USD
	nwbo	Issuance Of Common Stock And Warrants For Conversion Of Debt And Accrued Interest IssuanceOfCommonStockAndWarrantsForConversionOfDebtAndAccruedInterest	0	USD
	us-gaap	Notes Assumed1 NotesAssumed1	5175000	USD
	us-gaap	Notes Assumed1 NotesAssumed1	0	USD
	nwbo	Issuance Of Warrants In Conjunction With Note Payable IssuanceOfWarrantsInConjunctionWithNotePayable	139000	USD
	nwbo	Issuance Of Warrants In Conjunction With Note Payable IssuanceOfWarrantsInConjunctionWithNotePayable	0	USD
	us-gaap	Notes Reduction NotesReduction	3750000	USD
	us-gaap	Notes Reduction NotesReduction	0	USD
	us-gaap	Notes Issued1 NotesIssued1	1826000	USD
	us-gaap	Notes Issued1 NotesIssued1	0	USD
	nwbo	Extinguishment Of Shares Payable ExtinguishmentOfSharesPayable	0	USD
	nwbo	Extinguishment Of Shares Payable ExtinguishmentOfSharesPayable	22539000	USD
	nwbo	Extinguishment Of Derivative Liabilities ExtinguishmentOfDerivativeLiabilities	0	USD
	nwbo	Extinguishment Of Derivative Liabilities ExtinguishmentOfDerivativeLiabilities	10131000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	28000	USD
	nwbo	Issuance Of Common Stock For Debt Conversion IssuanceOfCommonStockForDebtConversion	0	USD
	nwbo	Issuance Of Common Stock For Debt Conversion IssuanceOfCommonStockForDebtConversion	934000	USD
	nwbo	Issuance Of Common Stock In Connection Conversion Of Notes Payable IssuanceOfCommonStockInConnectionConversionOfNotesPayable	0	USD
	nwbo	Issuance Of Common Stock In Connection Conversion Of Notes Payable IssuanceOfCommonStockInConnectionConversionOfNotesPayable	66000	USD
	nwbo	Return Of Common Stock And Warrants ReturnOfCommonStockAndWarrants	0	USD
	nwbo	Return Of Common Stock And Warrants ReturnOfCommonStockAndWarrants	8000	USD
CY2016Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32561000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	850000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	31711000	USD
CY2017Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8700000	shares
CY2017Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.20
CY2017Q3	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5500000	USD
	nwbo	Number Of Warrants Warrants Exercised On Cashless NumberOfWarrantsWarrantsExercisedOnCashless	16071000	shares
	nwbo	Weighted Average Exercise Price Warrants Exercised On Cashless WeightedAverageExercisePriceWarrantsExercisedOnCashless	0.20
CY2017Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-700000	USD
CY2017Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-400000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	50% will vest over a 24-month period in equal monthly installments, provided that the recipient continues to be employed by the Company. The unvested portions of the Options are subject to accelerated vesting upon (i) a change of effective control of the Company, (ii) the filing of the first Biologics License Application or other application for product approval in any jurisdiction, (iii) completion of any randomized clinical trial that meets its endpoint(s) (Phase II or Phase III), (iv) decision by the Board, in its discretion or (v) the death of the recipient.
CY2017Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	200000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	500000	USD
CY2017Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	27818000	USD
CY2017Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2612000	USD
CY2017Q3	nwbo	Fair Value Of Embedded Conversion Option FairValueOfEmbeddedConversionOption	1794000	USD
CY2017Q3	us-gaap	Long Term Debt LongTermDebt	27000000	USD
CY2017Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	32900000	shares
CY2017Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	7800000	USD
CY2017Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.48
CY2017Q3	nwbo	Shares Payable Current SharesPayableCurrent	2550000	USD
CY2016Q4	nwbo	Shares Payable Current SharesPayableCurrent	0	USD
	nwbo	Proceeds From Private Offering ProceedsFromPrivateOffering	2550000	USD
	nwbo	Proceeds From Private Offering ProceedsFromPrivateOffering	0	USD
	nwbo	Refund Of Vat Related To Uk Construction RefundOfVatRelatedToUkConstruction	220000	USD
	nwbo	Refund Of Vat Related To Uk Construction RefundOfVatRelatedToUkConstruction	0	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	2117000	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	825000	USD
	nwbo	Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise ReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise	3054000	USD
	nwbo	Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise ReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise	0	USD
	nwbo	Stock Issued During Period Value For Warrant Cashless Exercise StockIssuedDuringPeriodValueForWarrantCashlessExercise	7000	USD
	nwbo	Stock Issued During Period Value For Warrant Cashless Exercise StockIssuedDuringPeriodValueForWarrantCashlessExercise	0	USD
	nwbo	Adjustments To Additional Paid In Capital Reclassification Of Warrant Liabilities Related To Cashless Warrants Exercise AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiabilitiesRelatedToCashlessWarrantsExercise	3054000	USD
	nwbo	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Warrant Granted FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisWarrantGranted	17951000	USD
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	5264000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	3054000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2017Q3	nwbo	Proceeds From Private Offering ProceedsFromPrivateOffering	2600000	USD
CY2016Q3	nwbo	Shares Payable Current SharesPayableCurrent	2600000	USD
CY2017Q3	nwbo	Stock Issued During Period Shares Issued For Non Cash Consideration1 StockIssuedDuringPeriodSharesIssuedForNonCashConsideration1	6900000	shares
CY2017Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1300000	shares
CY2017Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.18
CY2017Q3	nwbo	Class Of Warrants Or Right Valueissued ClassOfWarrantsOrRightValueissued	4700000	USD
CY2017Q3	nwbo	Class Of Warrants Or Right Numberissued ClassOfWarrantsOrRightNumberissued	40400000	shares
CY2017Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	31000	USD
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	1100000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	218000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	211000	USD
CY2017Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	108000	USD
CY2017Q3	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	256000	USD
CY2017Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	668000	USD

Files In Submission

Name	View Source	Status
0001144204-17-060217-index-headers.html	Edgar Link	pending
0001144204-17-060217-index.html	Edgar Link	pending
0001144204-17-060217.txt	Edgar Link	pending
0001144204-17-060217-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nwbo-20170930.xml	Edgar Link	completed
nwbo-20170930.xsd	Edgar Link	pending
nwbo-20170930_cal.xml	Edgar Link	unprocessable
nwbo-20170930_def.xml	Edgar Link	unprocessable
nwbo-20170930_lab.xml	Edgar Link	unprocessable
nwbo-20170930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv479903_10q.htm	Edgar Link	pending
tv479903_ex31-1.htm	Edgar Link	pending
tv479903_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2017 Q3 Form 10-Q Financial Statement

#000114420417060217 Filed on November 20, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo

2017 Q3 Form 10-Q Financial Statement

#000114420417060217 Filed on November 20, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NWBO
NORTHWEST BIOTHERAPEUTICS INC Stock $nwbo